

ASX ANNOUNCEMENT

RESIGNATION OF DR SIMONE SCOVELL AS CHAIR

6 SEPTEMBER 2023

Melbourne, Australia - Vitura Health Limited (ASX:VIT) (Vitura and Company) advises that Dr Simone Scovell has today resigned as Chair and Independent Non-Executive Director of the Company.

Dr Scovell advised the Board that she was stepping aside after a record financial year at the helm of Vitura to turn her attention to personal business interests.

"Vitura is well placed to build on the many achievements of the past year and I wish the team every success," Dr Scovell said.

"I am immensely proud of the profit and growth Vitura has experienced in my time as Director and Chair.

"My personal business interests need a sustained increase in my time and energy and now is certainly the right time for me to step aside from Vitura, leaving it in really great shape.

"I am no longer able to give my Vitura commitments the time and attention required."

Dr Scovell, who joined the Vitura Board in September 2022 and was appointed Chair in February 2023, has also resigned as a member of the Company's Audit and Risk and Nomination and Remuneration Committees.

The Board acknowledges Dr Scovell's significant contribution to the Company and wishes her all the best in her future endeavours.

Following Dr Scovell's departure, Dr Marcia Walker will assume the role of interim Chair while a search for a new Independent Non-Executive Chair of the Board is conducted.

** ENDS **

VITURA HEALTH LIMITED

ASX : VIT

PO Box 6168, South Yarra

Victoria 3141, Australia

VITURA.COM.AU

BHC'S
CANVIEW

CDA
CLINICS

CORTEXA

cannadoc



About Vitura Health Limited

Vitura Health Limited is listed on the ASX (ASX:VIT) and, via its wholly owned subsidiaries, operates the following businesses:

- Burleigh Heads Cannabis - operates the market leading prescriber, patient, pharmacy and supplier online platform, CanView, which sells and distributes 260+ product SKUs within Australia under 39 international and domestic medicinal cannabis brands.
 - CanView is being developed to be a complete end-to-end healthcare ecosystem designed to provide doctors, pharmacists and patients with a simple and cost-effective way to facilitate the treatment of patients with increased efficiency and compliance. The CanView system is based on a medicines wholesaling platform which seamlessly brings together a number of disparate SAAS (software-as-a-service) providers including inventory control, invoicing, customer management, reporting and analytics, all linked together through customised integration from third party providers. Underpinning the suite of SAAS elements are a number of bespoke, internally-generated operating procedures and intellectual property assets, supported by the CanView customer support and infield customer engagement teams. Through the integration of the different elements which together make up CanView, the platform provides the best user experience in the industry.

Through the Company's relationships with third party integrators, CanView provides Australian doctors with the ability to integrate their patient management systems directly with the platform and to use their patient information to generate electronic prescriptions within the CanView platform, without the need to input the patient's details. Prescriptions are then sent directly to the CanView patient app where patients can manage their treatment and submit the prescription and subsequent repeats to one of the 4,000+ Australian pharmacies with accounts on CanView for dispensing.

While the Company's current operations focus on the sale and distribution of medicinal cannabis products, Vitura is fully licensed and equipped, via its two state-of-the-art distribution centres in Melbourne and the Gold Coast, to distribute all products under Schedules 2, 3, 4, 8 and 9. The establishment during the year of the Company's joint venture to distribute psychedelic products, including MDMA and synthetic Psilocybin, is a timely example of the opportunities that the Company believes can be seamlessly integrated into its existing digital health platform business.

- The Company owns 50% of Cortexa Pty Ltd, an incorporated joint venture with Canadian-based PharmAla Biotech (CSE:MDMA). Cortexa aims to be the leading supplier of psychedelics, GMP MDMA and GMP synthetic Psilocybin, for research and therapeutic use in Australia.
- The Company owns CDA Clinics that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.
- The Company owns 75.5% of Cannadoc Health Pty Ltd, a medicinal cannabis clinic business that undertakes nationwide telehealth consultations with patients seeking access to medicinal cannabis.

www.vitura.com.au

www.canview.com.au

www.burleighheadscannabis.com

www.cortexa.com.au

www.cdaclinics.com.au

www.cannadoc.com.au

**Authorised by**

Rodney Cocks, Chief Executive Officer and Executive Director

Contact**Vitura Health Limited**

Rodney Cocks

Chief Executive Officer and Executive Director

1300 799 491

info@vitura.com.au

Media enquiries

Tim Fogarty

The Civic Partnership

+61 400 179 075

tim.fogarty@civicpartners.com.au

Forward-looking statements

This announcement includes forward-looking statements which may be identified by words such as 'anticipates', 'believes', 'expects', 'intends', 'may', 'will', 'could', or 'should' and other similar words that involve risks and uncertainties. These forward-looking statements are based on the Company's expectations and beliefs concerning future events as at the date of this announcement. Forward-looking statements are necessarily subject to risks, uncertainties and other factors, many of which are outside the control of the Company, which could cause actual results to differ materially from such statements. The Company makes no undertaking to update or revise the forward-looking statements made in this announcement to reflect any change in circumstances or events after the date of this announcement.